Alpine Immune Sciences Funding & Investors
Seattle, WA
Alpine Immune Sciences, Inc. (AIS) focuses on developing novel protein-based cancer immunotherapies using its proprietary variant ig domain (vIgD) platform technology. The Company develops TIP technology, based on the vIgD platform, to enhance engineered cellular therapies. AIS offers a platform to interact with multiple targets, including many present in the immune synapse.
alpineimmunesciences.comTotal Amount Raised: $515,300,000
Alpine Immune Sciences Funding Rounds
Post Ipo Equity
$150,000,000
Post Ipo Equity
$100,000,000
Post Ipo Equity
$91,000,000
Post Ipo Equity Investors
Frazier ManagementLogos CapitalBiotechnology Value FundOrbiMed AdvisorsAvidity PartnersDecheng CapitalOmega Fund ManagementTCG Crossover ManagementPost Ipo Equity
$60,000,000
Post Ipo Equity Investors
Omega Fund ManagementAvidity PartnersEcoR1 CapitalSamsara BiocapitalPost Ipo Equity
$25,000,000
Post Ipo Equity Investors
Decheng CapitalOrbiMed AdvisorsFrazier ManagementAlpine BioVentures GPBiotechnology Value FundIPO
Unknown
Series A
$48,000,000
Series A Investors
OrbiMed AdvisorsFrazier ManagementAlpine BioVentures GPSeed
$1,300,000
Series Unknown
$30,000,000
Series Unknown Investors
Wellington ManagementRa Capital ManagementJennison AssociatesRock Springs CapitalSabby ManagementSeries B
$10,000,000
Series B Investors
Bridger ManagementTiger Global ManagementDeerfield Management
Funding info provided by Diffbot.